Wockhardt Shares Rally After U.S. FDA Approves Novel Antibiotic Zaynich

Shares of Wockhardt climbed sharply on Monday after the pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) had approved its novel antibiotic, Zaynich, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The approval represents a major achievement for the Mumbai-based drugmaker, which has spent years developing its proprietary antibiotic pipeline.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

The stock rose as much as 16.21% at the opening bell before trimming some gains. At 9:42 am, Wockhardt shares were trading 12.2% higher at ₹2,279 on the NSE.

Approval Targets Drug-Resistant Infections

Zaynich has been approved for treating complicated urinary tract infections caused by Gram-negative bacteria, including strains that have developed resistance to existing therapies. The approval comes as concerns grow about antimicrobial resistance, which has rendered several commonly used antibiotics less effective worldwide.

The latest clearance adds to Wockhardt’s regulatory achievements, as the company has now secured approvals for the drug in both India and the U.S. The development places Wockhardt among a limited number of Indian pharmaceutical companies to have successfully discovered and developed a novel antibiotic with international regulatory acceptance.

Years of Research Culminate in Regulatory Milestone

The approval marks the outcome of Wockhardt’s long-term investment in antibiotic research and development. Over the years, several large global pharmaceutical companies have reduced their focus on antibiotic discovery because of commercial challenges associated with the segment.

Wockhardt has continued to invest in developing treatments for resistant Gram-negative infections, which remain among the most difficult infectious disease threats due to their ability to evolve resistance against multiple drugs.

Earlier this year, Wockhardt Founder and Chairman Dr. Habil Khorakiwala, in an interview with Moneycontrol, said the company’s objective was not only to achieve scientific success but also to convert innovation into business growth.

Market Opportunity in India and Overseas

Around two million patients globally are affected by Gram-negative resistant infections. Wockhardt estimates that Zaynich addresses a total market opportunity of nearly $9 billion across the U.S., Europe and India.

In India, the company estimates that approximately 1.1 million resistant infection cases could potentially be treated with the drug, translating into a market opportunity of about ₹17,000 crore. Across the U.S. and European markets, the company estimates the addressable opportunity at around $7 billion.

With regulatory approvals now in place, attention is expected to shift toward the commercial rollout of Zaynich and its contribution to Wockhardt’s future revenue growth. The launch will also serve as a test of the company’s ability to convert years of research investment into a commercially successful pharmaceutical product.